$USNA

USNA vs. STVN: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Drugs stocks have likely encountered both USANA Health Sciences ( USNA Quick QuoteUSNA - ) and Stevanato Group ( STVN Quick QuoteSTVN - ) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.

Original reporting
Zacks Commentary · Zacks Equity Research
Published Sep 15, 2025, 3:40 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Sep 16, 2025, 12:32 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
USNA vs. STVN: Which Stock Is the Better Value Option? — source image
Decision brief

The 30-second read

$USNABullishMed
01

Why it matters

The bullish sentiment towards USNA suggests increased investor interest, potentially leading to short-term price appreciation.

02

Market read

The focus on USNA indicates a favorable outlook for its stock among value investors, with sector-wide implications for health sciences stocks.

03

What to watch

Potential regulatory changes or earnings reports could influence USNA's stock performance unexpectedly.

Timing: Immediate to short-term

Background

The article compares USNA and STVN to identify the more attractive value stock within the Medical - Drugs sector.

Company-level read

Ticker impact

$USNABullishMedium confidence
Context

High relevance due to bullish sentiment and industry significance.

Expected impact

Moderate increase in stock price over the next 1-3 months.

Evidence & confidence

Recent positive sentiment and industry relevance support upward movement, but lack of current technical data limits certainty.

$STVNNeutralLow confidence
Context

Low relevance due to minimal sentiment impact and industry overlap.

Expected impact

Limited or no significant price change expected.

Evidence & confidence

Low relevance score and neutral sentiment indicate minimal trading impact.

Market effects

Positive outlook for the Medical - Drugs sector, potentially benefiting related stocks.

Limited regional impact; primarily US-focused.

Moderate, as USNA operates globally and may influence sector sentiment.

Counterpoint

The positive sentiment may be overextended; a correction could occur if broader market conditions deteriorate.

Key entities

  • USANA Health Sciences

    A global health and wellness company specializing in nutritional and personal care products.

  • Stevanato Group

    A provider of drug containment and delivery systems.

Related articles

$STVNMedAI 8/10

Stevanato Group S.p.A. Q2 2026 Earnings Call Summary

Stevanato Group reported Q2 2026 revenue up 8%, with Biopharmaceutical and Diagnostic Solutions rising 9% and Engineering slightly down. High-value solutions grew 16% to 45% of revenue. Full-year 2026 guidance was raised to EUR 1.260-1.280 billion, citing a EUR 15 million Balda divestiture headwind. Alina variable dose pen received European regulatory approvals for liraglutide therapies.

$STVNMed

Stevanato (STVN) Q2 2026 Earnings Call Transcript

Stevanato Group (STVN) reported Q2 2026 revenue of EUR 302 million, up 8% year over year. High-value solutions rose 16% to EUR 135.9 million and were 45% of revenue. Gross margin increased 60 bps to 28.7%. Stevanato completed the sale of its California subsidiary Balda C. Brewer, recording EUR 12.2 million one-time expenses.

$USNAHigh

USANA HEALTH SCIENCES INC (USNA): Results of Operations and Financial Condition

USANA HEALTH SCIENCES INC (USNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026earningsreleaseex991.htm EX-99.1 Document USANA Health Sciences Reports Second Quarter 2026 Results Company Continues Evolution to a Diversified, Omnichannel Health and Wellness Business SALT LAKE CITY, August 4, 2026 (BUSINESS WIRE)—USANA Health Sciences, Inc. (N

$STVNMedAI 8/10

Stevanato Group S.p.A.: Stevanato Group Delivers 8% Revenue Growth for the Second Quarter of Fiscal 2026

Stevanato Group (NYSE: STVN) reported Q2 fiscal 2026 revenue up 8% to €302.0m, with high-value solutions up 16% to €135.9m (45% of sales). Adjusted EBITDA margin rose to 26.0%. The company completed the sale of its California subsidiary Balda C. Brewer, incurring €12.2m expenses, and updated FY2026 guidance to revenue €1.260-€1.280b and adjusted EBITDA €335.0-€345.2m.

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.